Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 10/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | DRD3 | P35462 | 2/20 | 0.36 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.36 |
| ▸ | CPT1A | P50416 | 1/20 | 0.34 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2890593 | 1.00 | GRM5 (0.46) | GRM5HCRTR1HCRTR2DRD2DRD3 | |
| SCHEMBL2896453 | 0.93 | GRM5 (0.44) | GRM5HCRTR1HCRTR2DRD2DRD3 | |
| SCHEMBL2897665 | 0.93 | GRM5 (0.55) | GRM5HCRTR1HCRTR2 | |
| SCHEMBL2896447 | 0.93 | GRM5 (0.44) | GRM5HCRTR1HCRTR2DRD2DRD3 | |
| SCHEMBL2897662 | 0.93 | GRM5 (0.55) | GRM5HCRTR1HCRTR2 | |
| SCHEMBL2890728 | 0.88 | HCRTR1 (0.38) | GRM5HCRTR1HCRTR2SCD5PIK3C3 | |
| SCHEMBL2890722 | 0.88 | HCRTR1 (0.38) | GRM5HCRTR1HCRTR2SCD5PIK3C3 | |
| SCHEMBL2893690 | 0.88 | GRM5 (0.55) | GRM5HCRTR1HCRTR2SCD5 | |
| SCHEMBL2893687 | 0.88 | GRM5 (0.55) | GRM5HCRTR1HCRTR2SCD5 | |
| SCHEMBL2894705 | 0.87 | GRM5 (0.37) | GRM5HCRTR1HCRTR2DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678796-B2 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2010-03-16 | — | — | US | claimed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | claimed |
| US-7678796-B2 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2010-03-16 | — | — | US | disclosed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259862-A1 | MGluR5 modulators I | GRM5, GRM1, GRIK5 | GRM5 1/4885HCRTR1 191/4885HCRTR2 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.